Forefronts in Nephrology: The molecular basis of renal cystic disease IV: The Etiology Of Hereditary Polycystic Disorders: Progress In Cloning Disease Genes: Progress in the cloning of ADPKD by Germino, G.G.
Forefronts in Nephrology: Renal cystic disease 729
following the identification of a gene defect in a relative. A third
is accessibility of genetic information by insurers and employers,
particularly as that information relates to the risk factors that go
into the calculation of insurance rates and to the competitive edge
achieved by an employer with a healthy workforce. These are
issues with no easy solutions, and ones that require careful
thought by individuals inside and outside the medical profession
to arrive at solutions that are equitable and acceptable to our
society.
Genetic study of ADPKD in Japan
E, Higashihara, and S. Hone
Kyorin University School of Medicine, Tokyo, Japan
Autosomal dominant polycystic kidney disease (ADPKD) is
one of the most common hereditaiy disorders and has unique
heterogeneity in both genetic and clinical features. First, a signif-
icant fraction of the ADPKD patient population is not linked to
the PKD1 locus located on the short arm of chromosome 16. It
has been estimated that this group (non-PKD1) constitute about
5 to 15% of all ADPKD patients, and no geographical clustering
has been observed so far. The clinical feature of a non-PKD1
patient is late onset of disease. These patients generally have a
better prognosis compared to PKD1 linked patients. Secondly,
although ADPKD is a progressive disease, end-stage renal disease
will occur in many but not all of the patients with non-PKD1.
Many patients are even asymptomatic.
In a national survey (P < 0.01), 3.9 per million Japanese
ADPKD patients annually develop end-stage renal disease com-
pared to 5.0 ADPKD patients per million patients in the United
States. The difference could be explained by multiple factors such
as race, diet, and medical delivery. ADPKD affects all races,
although whether this genetic heterogeneity exists in Asians has
not been studied.
We conducted a rapid genetic analysis of families with ADPKD
by means of an amplification of a microsatellite marker flanking
the PKD1 locus. The microsatellite D16S283 (SM7), which flanks
PKD1 proximally, was found to be highly polymorphic by Harris
et al. They noticed no recombination between PKD1 and SM7 in
90 informative meiosis. These studies were performed to deter-
mine if presymtomatic diagnosis of PKD1 linkage might make it
possible to intervene progressive renal failure by diet control and
medication. Previous work by other investigators has demon-
strated 11 genotypes of this marker in Caucasians. Nine genotypes
were isolated from the Japanease population tested. A total of 26
patient families (140 family members) were examined and 18
families were informative. Out of these 18 families, 14 (78%)
appeared to be linked to PKD1. Four families (22%) did not
follow PKD1 linkage, provided that no recombination occurred
bewteen PKD1 and SM7.
Although further studies are needed to identify the precise
genetic linkage for each family, the chances to be non-PKD1
linked are considered high in Japanese patients. The prognosis of
non-PKD1 linked patients have been found to be relatively better
compared to PKD1 linked patients. In 14 putitive PKD1 linked
families, 13 families have at least one member on dialysis. The
mean age of end-stage renal failure in this group is 50.8 (SD = 9.6).
In contrast, only one in 4 non-PKD1 linked families has a dialyzed
patient. Six families out of 24 (25%) were not imformative in this
study. Polymorphism was not informative in several cases, and
also the presence of shadow bands in gels sometimes caused
difficulties in the interpretation of genetic linkage.
Opportunities for the detection of ADPKD would be quite
different from country to country according to its medical delivery
system. These studies suggest that non-PKD1 linked families are
more prevelant in Japan as compared to the United States. This
rather ubiquitous presence of non-PKD1 linked families might
contribute to the fact that less ADPKD patients are dialyzed in
Japan compared to the United States.
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Progress in the cloning of ADPKD
G. G. Gerinino
The John Hopkins School of Medicine, Baltimore, Maryland, USA
It has been nine years since the most common form of
autosomal dominant polycystic kidney disease was first localized
to a 10-14 CM interval of chromosome 16pl3.3. This important
observation was soon followed by reports of more precise genetic
and physical maps that defined a candidate genomic interval of
approximately 500 kb. By 1991, virtually the entire genomic
segment and over 20 independent sets of candidate cDNA clones
had been isolated, and discovery of the disease gene appeared
imminent.
The PKD1 gene has remained elusive, however. There are a
number of unique aspects of the search for the PKD1 gene that
distinguish it from previous disease gene mapping expeditions and
account for its prolonged course. First, virtually all of the disease
genes successfully cloned to date have had clues betraying their
identity. The majority have been marked by chromosomal dele-
tions, rearrangements, or unstable elements. The remainder have
been identified on the basis of functional properties encoded by
their genes. We and others have searched the PKD1 interval for
similar hints without success. Southern blot hybridization studies
failed to detect disease-specific variants in the genomic restriction
maps for individuals affected with PKDI. A search for unstable
DNA elements also was unsuccessful.
Functional approaches have been limited by our incomplete
understanding of the pathogenesis of this disorder. Abnormalities
of tubular cell growth and differentiation, epithelial polarity, and
basement membrane composition are among the many differ-
ences observed between normal and cystic epithelia. Curiously,
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there is an abundance of candidate genes in the PKD1 interval
that encode proteins with functions that may play a role in
regulating cell growth, cell fate determination, and intracellular
protein sorting mechanisms. One of these, tuberin encodes a
GTPase that functions as a growth suppressor gene and is
mutated in 30% of all cases of tuberous sclerosis (TSC2). Angio-
myolipomas are the most common renal manifestation of this
disease, but renal cystic disease indistinguishable by ultrasonog-
raphy from that of ADPKD is also observed. Although it is
unlikely that the mutations of tuberin causes PKD1, a survey of
the list of candidates and their probable functions suggests a
clustering of genes with potentially complementary functions that
may be important for normal renal morphogenesis and function.
The discovery of abnormal expression in cystic kidneys of an
additional two novel genes whose functions are unknown further
supports this hypothesis. It would appear that there are an
overabundance of good candidates based on putative functions
and expression patterns.
The absence of clues to the identity of the PKD1 gene has
necessitated the use of laborious sequence-based techniques such
as direct genomic sequencing and single-strand conformational
analysis (SSCA). The search for PKD1 is uniquely complicated,
however, by the clustering of more than 20 candidate genes
encoding more than 60 kb of mRNA. The gene for cystic fibrosis,
CFTR, is the only example of a disease gene identified strictly on
the basis of oligo-base pair sequence abnormalities detected using
sequence-based approaches. CFTR was only one of a handful of
possible candidates for cystic fibrosis, and its genomic organiza-
tion strongly implicated it as a leading candidate.
A final unique feature of the PKD1 gene hunt is the extraor-
dinary complexity of the leading candidate gene, KG8. The gene
encodes a very large mRNA and maps adjacent to tuberin. The
latter observation is significant because it is possible that renal
cysts develop in the subset of patients with TSC2 that have
deletions which include nearby genes. Cloned cDNA fragments of
KG8 detect several mRNA species, the most common of which is
more than 12 kb in length and present in increased quantities in
cystic kidneys. Genomic analysis has revealed a bipartite structure
with a PKD1 locus-specific 3'-end and a 5' portion replicated in
multiple copies elsewhere on chromosome 16. Both intronic and
exonic sequences are conserved within this novel gene family. The
very high sequence similarity has greatly complicated the search
for mutations. Thus, we have developed gene product-base meth-
ods as a complementary approach. We hypothesize that disease-
producing mutations must somehow alter the protein product in
either quantitative of qualitative manner. These differences may
be detectable by either ID or 2D immunoblot analysis or by
immunolocalization studies. Antibodies generated against the 3'
PKD1-locus specific portion of the KG8 protein will be useful in
analyzing the protein product encoded by the PKD1 member of
this family.
In summary, there has been great progress in narrowing the size
of the genetic interval and isolating candidate genes. Major
obstacles to gene discovery have been the absence of clinical or
molecular clues, the large number of genes and the length of their
mRNA, and the replicated nature of a leading candidate. Several
complementary approaches are being employed to expedite gene
discovery: (a) molecular analysis of individuals with tuberous
sclerosis and renal cystic disease; (d) SSCA and direct genomic
sequencing of candidate genes; (c) characterization of proteins
encoded by candidate genes in the tissues of affected individuals.
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Genetic heterogeneity in medullary cystic kidney disease
C. Antignac
Hôpital Necker-Enfants Malades, Paris, France
Familial juvenile nephronophthisis (NPH) or recessive medul-
lary cystic kidney disease is an autosomal recessive kidney disor-
der. It is the most frequent genetic cause of end-stage renal
disease (ESRD) in childhood, accounting for 6% to 10% of
ESRD in children in Europe. NPH is characterized by chronic
tubulointerstitial nephritis and the presence of cysts in the me-
dulla, the latter being a late manifestation of the disease. The
early tubular basement membrane (TBM) abnormalities and the
inability to label the TBM with certain anti-TBM autoantibodies
suggest that the fundamental defect in NPH might be the produc-
tion of an abnormal TBM. However, the biochemical defect is
unknown. A number of heterogeneous extra-renal abnormalities
have been described associated and segregating with this renal
disease. The most frequent is Leber amaurosis, characterized by
blindness in early infancy, occuring in 16% of the cases of NPH.
The subtype of NPH associated with Leber amaurosis is described
as Senior-Loken syndrome (SLS). Later onset with progressive
visual defect has also been reported. Occasionally, other abnor-
malities (cerebellar dysfunction, liver involvement or bone anom-
alies) have been described in association with the renal and ocular
symptoms.
We have previously shown that the purely renal form of NPH
maps to chromosome 2, since we obtained a significant lod score
of 4.79 at 0 = 0.058 at the locus D2S160 in 18 kindreds with NPH.
In contrast, the lod score in four families with SLS excluded up
to 9% recombination with this marker. These results, further
strengthened by heterogeneity tests, suggested genetic heteroge-
neity between NPH and SLS. Other researchers have recently
confirmed these results in 9 German families with NPH.
To map this NPH gene more precisely, we have now tested the
segregation of 6 new microsatellite markers and 5 additional
families. Haplotype analysis show uneqivocally that 4 NPH fam-
ilies are not linked to the chromosome 2 markers, although there
is no clinical or pathological feature discernible in these families
